Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

20 Aug 2018

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

A new study provides insights into the degree to which socioeconomic status explains racial and ethnic disparities in childhood cancer survival.

20 Aug 2018

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials

When enrolled in a cancer clinical trial, the differences in survival rates between rural and urban patients are significantly reduced, SWOG study results show.

17 Aug 2018

Study provides new insight into how 'trash bag of the cell' traps and seals off waste

The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, much like a trash bag.

16 Aug 2018

Study reveals role of RUNX proteins in DNA repair

A study by researchers from the Cancer Science Institute of Singapore at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia pathway.

15 Aug 2018

Scientists identify stress hormone as key factor in failure of immune system to inhibit leukemia

The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.

14 Aug 2018

New discovery could pave way for improved leukemia treatment

Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukemia patients possess this favorable mutation, but until now, how it helps improve outcomes has remained unknown.

9 Aug 2018

Combination of arsenic and existing leukemia drug may combat cancer

Investigators have discovered that arsenic in combination with an existing leukemia drug work together to target a master cancer regulator.

9 Aug 2018

Ivosidenib receives FDA approval to treat acute myeloid leukemia patients with IDH1 mutation

Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

30 Jul 2018

Answer to decades-old mystery may allow some children to avoid bone marrow transplantation

Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder.

27 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

20 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Researchers map family trees of cancer cells to understand how AML responds to new drug

For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia to understand how this blood cancer responds to a new drug, enasidenib.

17 Jul 2018

Researchers uncover molecular drivers of a deadly pediatric cancer

Researchers have made important discoveries about the molecular mechanisms driving acute myeloid leukemia (AML), a deadly pediatric cancer.

11 Jul 2018

Scientists discover new way to predict healthy individuals at risk of developing AML

An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia, an aggressive and often deadly blood cancer.

10 Jul 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Streamlining and translating basic science discoveries into the clinic

To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.

2 Jul 2018

Researchers show how mutant CALR protein triggers cancer

Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer. The findings may lead to the development of novel therapies for certain types of blood cancer.

28 Jun 2018

New guidelines recommend newborns with Down’s syndrome to receive leukemia test

New genetic testing has been developed at the University of Oxford to detect early signs of a potentially fatal condition that can also develop into full blown leukaemia in children with Down’s syndrome.

21 Jun 2018